OpenAI has officially acquired Orchestra Bio, a startup focused on developing AI agents designed to assist pharmaceutical companies with drug development processes. The announcement, shared exclusively with Axios, marks a strategic move by OpenAI to expand its influence within the life sciences sector.

According to the company, the Orchestra Bio team and their underlying technology will be integrated into 'Rosalind,' OpenAI’s existing suite of AI models and tools tailored for researchers. Orchestra’s platform is specifically engineered to allow scientists to delegate complex tasks, such as monitoring clinical studies and tracking data, to automated AI agents.

This acquisition reflects a broader trend among major AI developers, including competitors like Anthropic, to diversify their capabilities beyond traditional strengths in coding and cybersecurity. By moving into the life sciences, these companies are seeking to apply large-scale AI models to high-stakes industries like drug discovery. While the financial terms of the deal were not disclosed, the integration signals OpenAI's intent to position itself as a primary infrastructure provider for scientific research and pharmaceutical development.